Cargando…

Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers

BACKGROUND: Head and neck cancers (HNC) are aggressive tumours. Overexpression of p16 in HNC correlates with human papilloma virus (HPV)-associated HNC that carry a better prognosis than HPV-negative tumours. Angiogenesis is an important factor in tumour progression. Our aim was to dissect the impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Baruah, P, Lee, M, Wilson, P O G, Odutoye, T, Williamson, P, Hyde, N, Kaski, J C, Dumitriu, I E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647678/
https://www.ncbi.nlm.nih.gov/pubmed/26171937
http://dx.doi.org/10.1038/bjc.2015.251
_version_ 1782401152050003968
author Baruah, P
Lee, M
Wilson, P O G
Odutoye, T
Williamson, P
Hyde, N
Kaski, J C
Dumitriu, I E
author_facet Baruah, P
Lee, M
Wilson, P O G
Odutoye, T
Williamson, P
Hyde, N
Kaski, J C
Dumitriu, I E
author_sort Baruah, P
collection PubMed
description BACKGROUND: Head and neck cancers (HNC) are aggressive tumours. Overexpression of p16 in HNC correlates with human papilloma virus (HPV)-associated HNC that carry a better prognosis than HPV-negative tumours. Angiogenesis is an important factor in tumour progression. Our aim was to dissect the impact of p16 expression on angiogenesis factors in HNC. METHODS: Eighteen newly diagnosed HNC patients and controls were analysed. Eleven pro- and anti-angiogenesis factors were quantified using multiplex ELISA in HNC patients and controls. Angiogenesis factors were analysed in tumour tissue using immunohistochemistry. RESULTS: Circulating levels of endostatin (anti-angiogenesis factor) were higher in the HNC group compared with healthy donors. Interestingly, the pro-angiogenesis factors angiopoietin-1 and vascular endothelial growth factor (VEGF) were significantly higher in patients with p16-negative compared with p16-positive HNC. Moreover, the major source of VEGF in p16-positive HNC tissue was tumour stromal cells. In contrast, both tumour cells and stromal cells expressed VEGF in p16-negative tissue. CONCLUSIONS: We show that p16-negative tumours associate with increased circulating levels of pro-angiogenic VEGF and angiopoietin-1. Tissue expression of VEGF differs between p16-positive and p16-negative tumours. These findings may explain differences in the biological behaviour of p16-positive and p16-negative HNC. Better understanding of mechanisms by which the p16 status influences tumour angiogenesis may guide the development of targeted therapies.
format Online
Article
Text
id pubmed-4647678
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46476782016-08-11 Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers Baruah, P Lee, M Wilson, P O G Odutoye, T Williamson, P Hyde, N Kaski, J C Dumitriu, I E Br J Cancer Molecular Diagnostics BACKGROUND: Head and neck cancers (HNC) are aggressive tumours. Overexpression of p16 in HNC correlates with human papilloma virus (HPV)-associated HNC that carry a better prognosis than HPV-negative tumours. Angiogenesis is an important factor in tumour progression. Our aim was to dissect the impact of p16 expression on angiogenesis factors in HNC. METHODS: Eighteen newly diagnosed HNC patients and controls were analysed. Eleven pro- and anti-angiogenesis factors were quantified using multiplex ELISA in HNC patients and controls. Angiogenesis factors were analysed in tumour tissue using immunohistochemistry. RESULTS: Circulating levels of endostatin (anti-angiogenesis factor) were higher in the HNC group compared with healthy donors. Interestingly, the pro-angiogenesis factors angiopoietin-1 and vascular endothelial growth factor (VEGF) were significantly higher in patients with p16-negative compared with p16-positive HNC. Moreover, the major source of VEGF in p16-positive HNC tissue was tumour stromal cells. In contrast, both tumour cells and stromal cells expressed VEGF in p16-negative tissue. CONCLUSIONS: We show that p16-negative tumours associate with increased circulating levels of pro-angiogenic VEGF and angiopoietin-1. Tissue expression of VEGF differs between p16-positive and p16-negative tumours. These findings may explain differences in the biological behaviour of p16-positive and p16-negative HNC. Better understanding of mechanisms by which the p16 status influences tumour angiogenesis may guide the development of targeted therapies. Nature Publishing Group 2015-08-11 2015-07-14 /pmc/articles/PMC4647678/ /pubmed/26171937 http://dx.doi.org/10.1038/bjc.2015.251 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Molecular Diagnostics
Baruah, P
Lee, M
Wilson, P O G
Odutoye, T
Williamson, P
Hyde, N
Kaski, J C
Dumitriu, I E
Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title_full Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title_fullStr Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title_full_unstemmed Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title_short Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
title_sort impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647678/
https://www.ncbi.nlm.nih.gov/pubmed/26171937
http://dx.doi.org/10.1038/bjc.2015.251
work_keys_str_mv AT baruahp impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT leem impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT wilsonpog impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT odutoyet impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT williamsonp impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT hyden impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT kaskijc impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers
AT dumitriuie impactofp16statusonproandantiangiogenesisfactorsinheadandneckcancers